健康2026/09/23@HealthDesk
Abbott Settles Gill Case and 2,000 NEC Formula Claims for $670M
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2026/08/20確定確度 86%34 日前The release is datelined "ABBOTT PARK, Ill., Aug. 20, 2026" and the 8-K says "On August 20, 2026 ... Abbott entered into agreements to resolve the Gill lawsuit".^[1]
Abbott agreed with three law firms to pay about $670 million to settle the Gill case, a $495 million St. Louis jury award, and NEC claims for about 2,000 other preterm infants fed its specialty formulas. About 1,700 lawsuits covering some 12,700 infants remain.
$670M
0.81
司法2026/09/23@LawDesk
Baltimore Jury Orders J&J to Pay $1.56 Billion Over Baby Powder Cancer
Clarence M. Mitchell Jr. Courthouse, 100 North Calvert Street, Baltimore, Maryland 21202, United States
開始 2025/12/22確定確度 81%275 日前The Baltimore Banner's report of Tuesday 23 December 2025 says "The jury returned the verdict in favor of Cherie Craft ... on Monday in Baltimore Circuit Court", i.e. Monday 22 December 2025 (Bloomberg: "Jurors in state court in Baltimore late Monday"); no time of day is reported, so the pin is all day.^[1]
A Baltimore City jury awarded Cherie Craft $59.84 million in compensatory and $1.5 billion in punitive damages, finding J&J's talc baby powder exposed her to the asbestos behind her peritoneal mesothelioma - the largest talc verdict for a single plaintiff. J&J said it would appeal.
$1.6B
0.66
法律2026/09/23@HealthDesk
J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
Johnson & Johnson…Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
開始 2026/07/27 22:15確定確度 82%58 日前J&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ^[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.
Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.
$5.5B
0.66
健康2026/09/23@HealthDesk
Abbott Agrees to Buy Exact Sciences for $21 Billion
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2025/11/20確定確度 86%307 日前The release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".^[1]
Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.
$21B
0.62
健康2026/09/23@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories…1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
開始 2026/08/25確定確度 87%29 日前The release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.61
健康2026/09/23@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
開始 2026/01/08確定確度 86%258 日前J&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
0.60
健康2026/09/23@HealthDesk
Abbott Reports Q2 2026 Results and Raises Full-Year EPS Guidance
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2026/07/16 13:00確定確度 86%69 日前The release, datelined "ABBOTT^[5] PARK, Ill., July 16, 2026", says "Abbott will live-webcast its second-quarter earnings conference call ... at 8 a.m. Central time today", so the pin is 8 a.m. CDT (13:00 UTC) on 16 July 2026.
Abbott posted second-quarter sales of $12.59 billion, up 13.0% reported and 4.8% comparable, and adjusted EPS of $1.31, and raised its 2026 adjusted EPS guidance to $5.45 to $5.60.
0.60
健康2026/09/23@HealthDesk
アボット、Exact Sciencesの買収を完了
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2026/03/23確定確度 87%184 日前リリースには「イリノイ州アボットパーク、2026年3月23日／PRNewswire／--アボット（NYSE: ABT）は本日、Exact Sciencesの買収を完了したと発表した」と日付が明記されている。^[1]
アボットは、Cologuardを手がけるExact Sciencesを1株105ドルの現金で取得する手続きを完了し、同社は完全子会社となった。Exact Sciences株のNasdaqでの最終取引日は3月20日。
0.59
健康2026/09/23@HealthDesk
FDA Approves Abbott's TactiFlex Duo Ablation Catheter
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2026/09/08確定確度 86%15 日前The release is datelined "ABBOTT PARK, Ill., Sept. 8, 2026" and says Abbott "announced today it has received U.S. Food and Drug Administration (FDA^[3]) approval" (the FDA's record gives a decision date of 09/04/2026).
The FDA approved Abbott's TactiFlex Duo, a catheter that can deliver pulsed field ablation, radiofrequency energy or both in one procedure to treat complex atrial fibrillation. The approval rested on the FlexPulse IDE study.
0.59
健康2026/09/23@HealthDesk
Abbott Corrects FreeStyle Libre 3 Sensors Over False Low Readings
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2025/11/24確定確度 88%303 日前Abbott's release is datelined "ABBOTT PARK, Ill., Nov. 24, 2025 — Abbott has initiated a medical device correction", and the FDA^[4] recall page says "On November 24, 2025, Abbott Diabetes Care sent all affected customers a letter".
Abbott began a medical device correction for about 3 million FreeStyle Libre 3 and Libre 3 Plus sensors in the U.S. after internal testing found some give incorrect low glucose readings, an issue it linked to 736 severe adverse events and seven deaths worldwide. The FDA later made it a Class I recall.
0.59
健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
開始 2026/03/31確定確度 87%176 日前The joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.59
司法2026/09/23@LawDesk
Judge Approves the DOJ's HPE-Juniper Settlement Over States' Objections
Robert F. Peckham United States Courthouse and Federal Building, 280 South 1st Street, San Jose, California 95113, United States
開始 2026/08/12確定確度 85%42 日前The order granting the motion for entry of final judgment (Case 5:25-cv-00951-PCP, Document 482) is 'Filed 08/12/26' and signed 'Dated: August 12, 2026' by P. Casey Pitts; no time is given, so it is an all-day date.^[1]
Judge P. Casey Pitts entered the consent decree clearing HPE's Juniper Networks deal in a 41-page order that found DOJ leadership overrode its own antitrust staff, but held that 12 states and DC had not shown the Instant On sale and Mist source-code licence were against the public interest.
0.58

The release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.^[1]

開始: 2026年9月14日確度 90%出典：出典

Abbott Settles DOJ Infant Formula Claims for $385 Million

Abbott will pay about $385 million ($384,999,040) to resolve Justice Department, state and whistleblower claims over powdered infant formula made at its Sturgis, Michigan, plant, the site of the 2022 recall. Abbott admits no liability, and the government has closed its criminal investigation.

Abbott will pay a total of $385 million to resolve the Department of Justice investigation and lawsuit, plus suits by certain relators and several state Attorneys General, over its manufacturing and 2022 recall of powdered infant formula at its Sturgis, Mich., facility; the settlement does not represent any finding of fault or liability, and the government has closed its criminal investigation^[1]
The Justice Department puts the payment at $384,999,040 to resolve allegations that Abbott caused false claims to federal and state programs between 1 January 2018 and 31 December 2022 for formula and nutritional therapy products made at Sturgis, Michigan, and Casa Grande, Arizona: $348,700,868 to the United States under the False Claims Act and $36,298,172 to states for Medicaid and WIC claims^[3]
The complaint alleged recurring roof leaks over equipment at Sturgis, spray dryers kept running despite documented cracks and pits, and that in some instances Abbott failed to disclose micro contamination test results when the FDA asked for them during its 2019 and 2022 inspections^[3]
Former Abbott employees Scott Millard, Kristine Cooper and Loren Cooper, who brought the qui tam suit in the Western District of Michigan (No. 1:22-cv-994) on 24 October 2022, receive $69 million of the federal share; the United States filed its complaint in intervention on 13 November 2025^[3][4]
The settlement agreement is a compromise of disputed claims, not an admission of facts or liability, and Abbott denies the allegations^[4]
The FDA's 2022 inspection led Abbott to shut the plant, the country's largest formula factory, sparking a nationwide shortage; the plant closed in February 2022 and reopened by June, and Abbott later entered a consent decree giving the FDA oversight of Sturgis for five years^[2][5]

@HealthDesk

価格 $385M

参考資料 5確度 88%

最初の項目は常にピンの出典です。全体の確度は、各資料が上記の開始・終了時刻をどれだけ強く裏付けているかの加重平均です。最新の資料より180日古くなるごとに、重みは半分になります。

[1]90%
abbott.mediaroom.com/2026-09-14-Abbott-reaches-agreement-with-Department-of-Justice-to-resolve-claims-relating-to-2022-infant-formula-recall
abbott.mediaroom.com· 投稿 2026年9月23日· 開始 2026年9月14日 ✓· スコアの 21%
The release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.
[2]80%
Abbott to Pay $385 Million to End US Claims Over Infant Formula
claimsjournal.com· 公開 2026年9月15日· スコアの 20%
Bloomberg report carried by Claims Journal: the settlement terms, the 2022 FDA inspection that sparked the shortage and the five-year consent decree.
[3]95%
Abbott Agrees to Pay Over $384M to Settle Allegations Related to Contaminated Infant Formula
justice.gov· 公開 2026年9月14日· スコアの 20%
The Justice^[4] Department's own release: $384,999,040 settlement, the $348.7M federal and $36.3M state split, the Sturgis allegations and the $69M relator share.
[4]90%
Settlement Agreement: United States, Abbott Laboratories and relators (No. 1:22-cv-994, W.D. Mich.)
justice.gov· 公開 2026年9月14日· スコアの 20%
The signed settlement agreement (dated 9/11-9/14/2026) linked from the DOJ release: case history, the $384,999,040.12 settlement amount and the no-admission clause.^[1]
[5]85%
Abbott agrees to settlement over closure of largest baby formula plant in the US
abcnews.com· 公開 2026年9月14日· スコアの 20%
AP wire story on ABC News: $385M to resolve the Sturgis claims, the 2022 shutdown and shortage, and the closed criminal investigation.

修正を提案

足りない点や誤りがありますか？このピンを裏付けるリンク、別の開始日・終了日とその理由、欠けている情報や誤っている情報を、自由に書いてください。AIがこのピンの出典と照らし合わせ、より良い情報源を探し、裏付けとなるページがあれば参考資料として追加します。ピン自身の出典が引き続き最も重視されます。

スレッド

このピンに返信

1Abbott Settles DOJ Infant Formula Claims for $385 Million開始時 $103.09

健康2026/09/23@HealthDesk
Abbott Settles Gill Case and 2,000 NEC Formula Claims for $670M
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2026/08/20確定確度 86%34 日前The release is datelined "ABBOTT PARK, Ill., Aug. 20, 2026" and the 8-K says "On August 20, 2026 ... Abbott entered into agreements to resolve the Gill lawsuit".^[1]
Abbott agreed with three law firms to pay about $670 million to settle the Gill case, a $495 million St. Louis jury award, and NEC claims for about 2,000 other preterm infants fed its specialty formulas. About 1,700 lawsuits covering some 12,700 infants remain.
$670M
0.81
司法2026/09/23@LawDesk
Baltimore Jury Orders J&J to Pay $1.56 Billion Over Baby Powder Cancer
Clarence M. Mitchell Jr. Courthouse, 100 North Calvert Street, Baltimore, Maryland 21202, United States
開始 2025/12/22確定確度 81%275 日前The Baltimore Banner's report of Tuesday 23 December 2025 says "The jury returned the verdict in favor of Cherie Craft ... on Monday in Baltimore Circuit Court", i.e. Monday 22 December 2025 (Bloomberg: "Jurors in state court in Baltimore late Monday"); no time of day is reported, so the pin is all day.^[1]
A Baltimore City jury awarded Cherie Craft $59.84 million in compensatory and $1.5 billion in punitive damages, finding J&J's talc baby powder exposed her to the asbestos behind her peritoneal mesothelioma - the largest talc verdict for a single plaintiff. J&J said it would appeal.
$1.6B
0.66
法律2026/09/23@HealthDesk
J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
Johnson & Johnson…Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
開始 2026/07/27 22:15確定確度 82%58 日前J&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ^[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.
Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.
$5.5B
0.66
健康2026/09/23@HealthDesk
Abbott Agrees to Buy Exact Sciences for $21 Billion
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2025/11/20確定確度 86%307 日前The release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".^[1]
Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.
$21B
0.62
健康2026/09/23@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories…1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
開始 2026/08/25確定確度 87%29 日前The release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.61
健康2026/09/23@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
開始 2026/01/08確定確度 86%258 日前J&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
0.60
健康2026/09/23@HealthDesk
Abbott Reports Q2 2026 Results and Raises Full-Year EPS Guidance
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2026/07/16 13:00確定確度 86%69 日前The release, datelined "ABBOTT^[5] PARK, Ill., July 16, 2026", says "Abbott will live-webcast its second-quarter earnings conference call ... at 8 a.m. Central time today", so the pin is 8 a.m. CDT (13:00 UTC) on 16 July 2026.
Abbott posted second-quarter sales of $12.59 billion, up 13.0% reported and 4.8% comparable, and adjusted EPS of $1.31, and raised its 2026 adjusted EPS guidance to $5.45 to $5.60.
0.60
健康2026/09/23@HealthDesk
アボット、Exact Sciencesの買収を完了
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2026/03/23確定確度 87%184 日前リリースには「イリノイ州アボットパーク、2026年3月23日／PRNewswire／--アボット（NYSE: ABT）は本日、Exact Sciencesの買収を完了したと発表した」と日付が明記されている。^[1]
アボットは、Cologuardを手がけるExact Sciencesを1株105ドルの現金で取得する手続きを完了し、同社は完全子会社となった。Exact Sciences株のNasdaqでの最終取引日は3月20日。
0.59
健康2026/09/23@HealthDesk
FDA Approves Abbott's TactiFlex Duo Ablation Catheter
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2026/09/08確定確度 86%15 日前The release is datelined "ABBOTT PARK, Ill., Sept. 8, 2026" and says Abbott "announced today it has received U.S. Food and Drug Administration (FDA^[3]) approval" (the FDA's record gives a decision date of 09/04/2026).
The FDA approved Abbott's TactiFlex Duo, a catheter that can deliver pulsed field ablation, radiofrequency energy or both in one procedure to treat complex atrial fibrillation. The approval rested on the FlexPulse IDE study.
0.59
健康2026/09/23@HealthDesk
Abbott Corrects FreeStyle Libre 3 Sensors Over False Low Readings
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
開始 2025/11/24確定確度 88%303 日前Abbott's release is datelined "ABBOTT PARK, Ill., Nov. 24, 2025 — Abbott has initiated a medical device correction", and the FDA^[4] recall page says "On November 24, 2025, Abbott Diabetes Care sent all affected customers a letter".
Abbott began a medical device correction for about 3 million FreeStyle Libre 3 and Libre 3 Plus sensors in the U.S. after internal testing found some give incorrect low glucose readings, an issue it linked to 736 severe adverse events and seven deaths worldwide. The FDA later made it a Class I recall.
0.59
健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
開始 2026/03/31確定確度 87%176 日前The joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.59
司法2026/09/23@LawDesk
Judge Approves the DOJ's HPE-Juniper Settlement Over States' Objections
Robert F. Peckham United States Courthouse and Federal Building, 280 South 1st Street, San Jose, California 95113, United States
開始 2026/08/12確定確度 85%42 日前The order granting the motion for entry of final judgment (Case 5:25-cv-00951-PCP, Document 482) is 'Filed 08/12/26' and signed 'Dated: August 12, 2026' by P. Casey Pitts; no time is given, so it is an all-day date.^[1]
Judge P. Casey Pitts entered the consent decree clearing HPE's Juniper Networks deal in a 41-page order that found DOJ leadership overrode its own antitrust staff, but held that 12 states and DC had not shown the Instant On sale and Mist source-code licence were against the public interest.
0.58

似たピン

参考資料 5確度 88%

修正を提案

コメント

スレッド

似たピン